CUYAHOGA FALLS, Ohio — Americhem said it will highlight a range of new polymer materials designed to address environmental, regulatory, and performance challenges in medical device manufacturing at Pharmapack in Paris and MD&M West in Anaheim in early 2026.
The company, which specializes in healthcare-focused polymer compounds and masterbatches, said the technologies reflect growing industry pressure to reduce environmental risk, improve component traceability, and accelerate development timelines as devices become more complex and regulated.
Among the technologies Americhem plans to feature are PFAS-free internally lubricated compounds under its EcoLube MD platform. The materials are engineered to reduce friction and wear without fluorinated additives and are intended for applications such as auto-injectors, wearable infusion pumps, and precision robotic instruments.
Americhem will also spotlight laser-marking-ready thermoplastics that enable permanent, high-contrast identification directly on molded plastic components. The materials are designed for cleanroom environments where labels and inks are impractical, supporting traceability and regulatory compliance throughout device lifecycles.
In addition, the company plans to present new high-performance transparent polymer alloys that offer alternatives to traditional clear materials, with improved toughness and resistance to repeated sterilization. These materials are aimed at structural medical components that require both visibility and durability.
The company said it is expanding its ColorRx masterbatch portfolio with regulatory-ready color solutions that are ISO 10993-tested and manufactured under cGMP conditions. The locked formulations are intended to help original equipment manufacturers address color compliance and consistency challenges.
Americhem will also highlight its nDryve additive technology for medical nonwovens, a PFAS-free, in-melt surface modifier developed to deliver fluid repellency for applications such as surgical gowns and hygiene drapes, in response to growing demand for fluorine-free materials.
Americhem said it is actively collaborating with OEM partners to co-develop and validate these technologies for next-generation medical devices. The company reported continued double-digit growth in its healthcare segment, supported by ISO 13485-certified manufacturing facilities in the United States and Denmark, with expansion into China planned for 2026.
“There’s a clear shift happening—material choices are now deeply tied to sustainability goals, regulatory scrutiny, and device functionality,” said Matt Miklos, Vice President of Corporate Strategy and M&A at Americhem. “What we’re bringing to these shows is not a catalog—it’s a pipeline of engineered solutions designed to be customized, scaled, and validated in partnership with OEMs who are navigating that complexity every day.”
Americhem said it will also participate in the SPE Minitec Conference held during MD&M West, contributing to technical discussions on materials innovation for evolving care models.
